Questcor Pharmaceuticals (QCOR) Posts Quarterly Earnings, Beats Expectations By $0.11 EPS
Questcor Pharmaceuticals (NASDAQ:QCOR) announced its earnings results on Thursday. The company reported $1.85 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.74 by $0.11, StockRatingsNetwork.com reports. The company had revenue of $278.80 million for the quarter, compared to the consensus estimate of $261.02 million. During the same quarter in the prior year, the company posted $1.12 earnings per share. The company’s quarterly revenue was up 38.5% on a year-over-year basis.
Questcor Pharmaceuticals (NASDAQ:QCOR) traded up 1.21% during mid-day trading on Thursday, hitting $97.17. 711,112 shares of the company’s stock traded hands. Questcor Pharmaceuticals has a one year low of $46.00 and a one year high of $97.80. The stock has a 50-day moving average of $92.09 and a 200-day moving average of $77.44. The company has a market cap of $5.747 billion and a P/E ratio of 18.13.
In other Questcor Pharmaceuticals news, Insider Don M. Bailey sold 40,000 shares of Questcor Pharmaceuticals stock on the open market in a transaction dated Monday, July 14th. The stock was sold at an average price of $95.54, for a total transaction of $3,821,600.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.
A number of analysts have recently weighed in on QCOR shares. Analysts at Zacks downgraded shares of Questcor Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday, July 1st. They now have a $97.00 price target on the stock. On the ratings front, analysts at Mizuho downgraded shares of Questcor Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, May 19th. They now have a $92.00 price target on the stock. Finally, analysts at Piper Jaffray downgraded shares of Questcor Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday, May 12th. They now have a $98.00 price target on the stock, up previously from $96.00. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $86.20.
Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.